Medical Care

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Research Report 2025

The global market for Chimeric Antigen Receptor (CAR)-T Cell Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chimeric Antigen Receptor (CAR)-T Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chimeric Antigen Receptor (CAR)-T Cell Therapy.
The Chimeric Antigen Receptor (CAR)-T Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chimeric Antigen Receptor (CAR)-T Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics
Segment by Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
Segment by Application
Hospital
Diagnostic Center
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Abecma
1.2.3 Breyanzi
1.2.4 Kymriah
1.2.5 Tecartus
1.2.6 Yescarta
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Perspective (2020-2031)
2.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Growth Trends by Region
2.2.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Market Size by Region (2020-2025)
2.2.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Region (2026-2031)
2.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Dynamics
2.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Trends
2.3.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
2.3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Challenges
2.3.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chimeric Antigen Receptor (CAR)-T Cell Therapy Players by Revenue
3.1.1 Global Top Chimeric Antigen Receptor (CAR)-T Cell Therapy Players by Revenue (2020-2025)
3.1.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue
3.4 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Concentration Ratio
3.4.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue in 2024
3.5 Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy Head office and Area Served
3.6 Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, Product and Application
3.7 Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Breakdown Data by Type
4.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Market Size by Type (2020-2025)
4.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Type (2026-2031)
5 Chimeric Antigen Receptor (CAR)-T Cell Therapy Breakdown Data by Application
5.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Market Size by Application (2020-2025)
5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2020-2031)
6.2 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025)
6.4 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2020-2031)
7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025)
7.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2020-2031)
8.2 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2020-2031)
9.2 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025)
9.4 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2020-2031)
10.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Autolus Therapeutics
11.1.1 Autolus Therapeutics Company Details
11.1.2 Autolus Therapeutics Business Overview
11.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.1.4 Autolus Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.1.5 Autolus Therapeutics Recent Development
11.2 CARsgen Therapeutics
11.2.1 CARsgen Therapeutics Company Details
11.2.2 CARsgen Therapeutics Business Overview
11.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.2.4 CARsgen Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.2.5 CARsgen Therapeutics Recent Development
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Details
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.3.4 Juno Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.3.5 Juno Therapeutics Recent Development
11.4 Sorrento Therapeutics
11.4.1 Sorrento Therapeutics Company Details
11.4.2 Sorrento Therapeutics Business Overview
11.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.4.4 Sorrento Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.4.5 Sorrento Therapeutics Recent Development
11.5 bluebird bio
11.5.1 bluebird bio Company Details
11.5.2 bluebird bio Business Overview
11.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.5.4 bluebird bio Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.5.5 bluebird bio Recent Development
11.6 CELGENE CORPORATION
11.6.1 CELGENE CORPORATION Company Details
11.6.2 CELGENE CORPORATION Business Overview
11.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.6.4 CELGENE CORPORATION Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.6.5 CELGENE CORPORATION Recent Development
11.7 Eureka Therapeutics
11.7.1 Eureka Therapeutics Company Details
11.7.2 Eureka Therapeutics Business Overview
11.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.7.4 Eureka Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.7.5 Eureka Therapeutics Recent Development
11.8 Avacta Life Sciences
11.8.1 Avacta Life Sciences Company Details
11.8.2 Avacta Life Sciences Business Overview
11.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.8.4 Avacta Life Sciences Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.8.5 Avacta Life Sciences Recent Development
11.9 Calyxt
11.9.1 Calyxt Company Details
11.9.2 Calyxt Business Overview
11.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.9.4 Calyxt Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.9.5 Calyxt Recent Development
11.10 Celyad Oncology SA
11.10.1 Celyad Oncology SA Company Details
11.10.2 Celyad Oncology SA Business Overview
11.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.10.4 Celyad Oncology SA Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.10.5 Celyad Oncology SA Recent Development
11.11 Fortress Biotech
11.11.1 Fortress Biotech Company Details
11.11.2 Fortress Biotech Business Overview
11.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.11.4 Fortress Biotech Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.11.5 Fortress Biotech Recent Development
11.12 IMMUNE THERAPEUTICS
11.12.1 IMMUNE THERAPEUTICS Company Details
11.12.2 IMMUNE THERAPEUTICS Business Overview
11.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.12.4 IMMUNE THERAPEUTICS Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.12.5 IMMUNE THERAPEUTICS Recent Development
11.13 Gilead Sciences
11.13.1 Gilead Sciences Company Details
11.13.2 Gilead Sciences Business Overview
11.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.13.4 Gilead Sciences Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.13.5 Gilead Sciences Recent Development
11.14 Novartis AG
11.14.1 Novartis AG Company Details
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.14.4 Novartis AG Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.14.5 Novartis AG Recent Development
11.15 Alaunos Therapeutics
11.15.1 Alaunos Therapeutics Company Details
11.15.2 Alaunos Therapeutics Business Overview
11.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.15.4 Alaunos Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.15.5 Alaunos Therapeutics Recent Development
11.16 Poseida Therapeutics
11.16.1 Poseida Therapeutics Company Details
11.16.2 Poseida Therapeutics Business Overview
11.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
11.16.4 Poseida Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
11.16.5 Poseida Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Abecma
Table 3. Key Players of Breyanzi
Table 4. Key Players of Kymriah
Table 5. Key Players of Tecartus
Table 6. Key Players of Yescarta
Table 7. Key Players of Others
Table 8. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Region (2020-2025)
Table 12. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Region (2026-2031)
Table 14. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends
Table 15. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
Table 16. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Challenges
Table 17. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
Table 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Players (2020-2025)
Table 20. Global Top Chimeric Antigen Receptor (CAR)-T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy as of 2024)
Table 21. Ranking of Global Top Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, Headquarters and Area Served
Table 24. Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, Product and Application
Table 25. Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Type (2020-2025)
Table 29. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Type (2026-2031)
Table 31. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Application (2020-2025)
Table 33. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Application (2026-2031)
Table 35. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 50. Autolus Therapeutics Company Details
Table 51. Autolus Therapeutics Business Overview
Table 52. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 53. Autolus Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 54. Autolus Therapeutics Recent Development
Table 55. CARsgen Therapeutics Company Details
Table 56. CARsgen Therapeutics Business Overview
Table 57. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 58. CARsgen Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 59. CARsgen Therapeutics Recent Development
Table 60. Juno Therapeutics Company Details
Table 61. Juno Therapeutics Business Overview
Table 62. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 63. Juno Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 64. Juno Therapeutics Recent Development
Table 65. Sorrento Therapeutics Company Details
Table 66. Sorrento Therapeutics Business Overview
Table 67. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 68. Sorrento Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 69. Sorrento Therapeutics Recent Development
Table 70. bluebird bio Company Details
Table 71. bluebird bio Business Overview
Table 72. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 73. bluebird bio Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 74. bluebird bio Recent Development
Table 75. CELGENE CORPORATION Company Details
Table 76. CELGENE CORPORATION Business Overview
Table 77. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 78. CELGENE CORPORATION Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 79. CELGENE CORPORATION Recent Development
Table 80. Eureka Therapeutics Company Details
Table 81. Eureka Therapeutics Business Overview
Table 82. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 83. Eureka Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 84. Eureka Therapeutics Recent Development
Table 85. Avacta Life Sciences Company Details
Table 86. Avacta Life Sciences Business Overview
Table 87. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 88. Avacta Life Sciences Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 89. Avacta Life Sciences Recent Development
Table 90. Calyxt Company Details
Table 91. Calyxt Business Overview
Table 92. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 93. Calyxt Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 94. Calyxt Recent Development
Table 95. Celyad Oncology SA Company Details
Table 96. Celyad Oncology SA Business Overview
Table 97. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 98. Celyad Oncology SA Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 99. Celyad Oncology SA Recent Development
Table 100. Fortress Biotech Company Details
Table 101. Fortress Biotech Business Overview
Table 102. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 103. Fortress Biotech Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 104. Fortress Biotech Recent Development
Table 105. IMMUNE THERAPEUTICS Company Details
Table 106. IMMUNE THERAPEUTICS Business Overview
Table 107. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 108. IMMUNE THERAPEUTICS Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 109. IMMUNE THERAPEUTICS Recent Development
Table 110. Gilead Sciences Company Details
Table 111. Gilead Sciences Business Overview
Table 112. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 113. Gilead Sciences Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 114. Gilead Sciences Recent Development
Table 115. Novartis AG Company Details
Table 116. Novartis AG Business Overview
Table 117. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 118. Novartis AG Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 119. Novartis AG Recent Development
Table 120. Alaunos Therapeutics Company Details
Table 121. Alaunos Therapeutics Business Overview
Table 122. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 123. Alaunos Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 124. Alaunos Therapeutics Recent Development
Table 125. Poseida Therapeutics Company Details
Table 126. Poseida Therapeutics Business Overview
Table 127. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product
Table 128. Poseida Therapeutics Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025) & (US$ Million)
Table 129. Poseida Therapeutics Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
Table 133. Authors List of This Report


List of Figures
Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
Figure 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Type: 2024 VS 2031
Figure 4. Abecma Features
Figure 5. Breyanzi Features
Figure 6. Kymriah Features
Figure 7. Tecartus Features
Figure 8. Yescarta Features
Figure 9. Others Features
Figure 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Application: 2024 VS 2031
Figure 12. Hospital Case Studies
Figure 13. Diagnostic Center Case Studies
Figure 14. Other Case Studies
Figure 15. Chimeric Antigen Receptor (CAR)-T Cell Therapy Report Years Considered
Figure 16. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Region: 2024 VS 2031
Figure 19. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Players in 2024
Figure 20. Global Top Chimeric Antigen Receptor (CAR)-T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor (CAR)-T Cell Therapy as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue in 2024
Figure 22. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Country (2020-2031)
Figure 24. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Country (2020-2031)
Figure 28. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Region (2020-2031)
Figure 36. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Country (2020-2031)
Figure 44. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Country (2020-2031)
Figure 48. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Autolus Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 52. CARsgen Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 53. Juno Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 54. Sorrento Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 55. bluebird bio Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 56. CELGENE CORPORATION Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 57. Eureka Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 58. Avacta Life Sciences Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 59. Calyxt Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 60. Celyad Oncology SA Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 61. Fortress Biotech Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 62. IMMUNE THERAPEUTICS Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 63. Gilead Sciences Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 64. Novartis AG Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 65. Alaunos Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 66. Poseida Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR)-T Cell Therapy Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies